Is ATHE or AVIR more undervalued in 2026?

CirclFi compares Alterity Therapeutics Limited (ATHE) and Atea Pharmaceuticals, Inc. (AVIR) using 13 institutional-grade valuation models. ATHE has a Quality of Company score of 1.8/10 while AVIR scores 4.2/10.

Which is a better buy — ATHE or AVIR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ATHE and AVIR valuations compare?

ATHE at $4.12 and AVIR at $4.67 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ATHE vs AVIR Valuation Comparison 2026 — Intrinsic Value Analysis

ATHE

Pharmaceutical Preparations

Alterity Therapeutics Limited

Quality

1.8

out of 10

Value Trap

—

Price

$4.12

Last close

Models

7/13

Active

AVIR

Pharmaceutical Preparations

Atea Pharmaceuticals, Inc.

Quality

4.2

out of 10

Value Trap

SAFE

Price

$4.67

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	ATHE Fair Value	ATHE Upside	AVIR Fair Value	AVIR Upside
Bayesian DCF	Intrinsic	$1.11	-73.1%	$1.37	-70.6%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.20	-95.3%	$0.59	-89.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATHE vs AVIR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATHE vs AVIR — Which Stock Is More Undervalued?

AVIR scores higher with a 4.2/10 quality rating vs ATHE's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alterity Therapeutics Limited (ATHE) and Atea Pharmaceuticals, Inc. (AVIR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATHE currently trades at $4.12 with a QOC of 1.8/10, while AVIR trades at $4.67 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).